BioSpace News Archive

Eisai Inc. and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor LENVIMA® (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

PURE Bioscience , Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that it has closed on an approximately $1.5 million private placement with existing shareholders.

Over the last several years, there’s been growing scientific and public interest in the role of microorganisms in the maintenance of overall health and prevention and treatment of disease.

Efforts to curb opioid use in California workers’ compensation have been successful, but new research by the California Workers’ Compensation Institute (CWCI) shows they remain very common among claims in which injured workers are given multiple concurrent prescriptions, and are the most prevalent type of drug found in polypharmacy claims that involve five or more concurrent prescriptions.

SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD; OTCQB: SQIDF), today reported its financial and operational results for the three and nine months ended June 30, 2018.

The Alzheimer’s Research and Prevention Foundation (ARPF) will host its second Brain Longevity® Therapy Training on October 12-14 at American University Washington College of Law in Washington, D.C. The training will help advance ARPF’s mission to equip both the public as well as wellness and health care leaders to promote prevention strategies that help to prevent Alzheimer’s disease.

Brightline Initiative Dedicated to Bridging the Gap Between Strategy Design and Delivery

Pediatric Therapy Services, LLC, who operates as The Stepping Stones Group, a provider of therapy and education solutions to children with special needs and autism in educational settings, has made the Inc. 5000, the most prestigious ranking of the nation’s fastest-growing private companies, for the third time.

The U.S. Food and Drug Administration today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds.

Conference to showcase new research and recognize winners of SLAM Competition